Following these impressive results in type 2 diabetes, trials were carried outto assess the impact of SGLT2 inhibitors in patients with chronic kidney disease(CKD) and chronic heart failure (CHF), irrespective of their diabetic status. Here, SLC5A2 is linked to type 2 diabetes mellitus.